271 related articles for article (PubMed ID: 27896507)
1. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
[TBL] [Abstract][Full Text] [Related]
2. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
3. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Ørbo A; Arnes M; Vereide AB; Straume B
BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
5. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
[TBL] [Abstract][Full Text] [Related]
6. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
Abu Hashim H; Ghayaty E; El Rakhawy M
Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
Wan YL; Holland C
Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
[TBL] [Abstract][Full Text] [Related]
9. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
10. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
12. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
Orbo A; Vereide A; Arnes M; Pettersen I; Straume B
BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
[TBL] [Abstract][Full Text] [Related]
14. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
15. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
16. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
[TBL] [Abstract][Full Text] [Related]
17. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
18. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
[TBL] [Abstract][Full Text] [Related]
19. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
